Cited by 237Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchGenetic Associations and Epidemiology

Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals

Open access
Corneveaux, Jason J., Myers, Amanda J., Allen, April N., Pruzin, Jeremy J., Ramirez, Manuel, Engel, Anzhelika, Nalls, Michael A., Chen, Kewei +20 more·2010·Human Molecular Genetics

Abstract

In this study, we assess 34 of the most replicated genetic associations for Alzheimer's disease (AD) using data generated on Affymetrix SNP 6.0 arrays and imputed at over 5.7 million markers from a unique cohort of over 1600 neuropathologically defined AD cases and controls (1019 cases and 591 controls). Testing the top genes from the AlzGene meta-analysis, we confirm the well-known association with APOE single nucleotide polymorphisms (SNPs), the CLU, PICALM and CR1 SNPs recently implicated in unusually large data sets, and previously implicated CST3 and ACE SNPs. In the cases of CLU, PICALM and CR1, as well as in APOE, the odds ratios we find are slightly larger than those previously reported in clinical samples, consistent with what we believe to be more accurate classification of disease in the clinically characterized and neuropathologically confirmed AD cases and controls.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddq221

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The association of PICALM polymorphisms with late-onset AD has been reported by the majority of GWAS studies.

    “The association of PICALM polymorphisms with late-onset AD has been reported by the majority of GWAS studies (94, 119, 236, 265, 298, 344, 528).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [119]

    The Introduction reports that two large studies identified PICALM as a late-onset Alzheimer’s disease risk locus, and the Results report an association for PICALM in this cohort. The paper does not establish that a majority of GWAS studies reported the association. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • APOE4 increases the risk for developing Alzheimer's disease by 2.5-4-fold in heterozygous carriers and 12-15-fold in homozygous carriers.

    “APOE4 increases the risk for developing AD by 2.5-4-fold in heterozygous and 12-15-fold in homozygous carriers (Corder et al., 1993; Grupe et al., 2007; Corneveaux et al., 2010), however the risk is affected by factors such as sex or population ancestry (Belloy et al., 2023).”

    From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Corneveaux et al., 2010

    The Introduction identifies APOE ε4 as a well-replicated risk factor for late-onset Alzheimer’s disease. The Results do not give the claimed 2.5–4-fold estimate for heterozygotes; for ε4 homozygotes, they report an odds ratio of about 20 in this cohort and cite about 13 from AlzGene. Thus the paper supports increased risk, but not both numerical ranges as stated. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Some additional highly replicated AD risk genes include CR1, BIN1, and TREM2.

    “Some additional highly replicated risk genes include CR1 , BIN1 , and TREM2 (94, 119, 219, 300, 344, 543).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [119]

  • Several GWAS studies have identified CLU as a significant genetic risk factor for sporadic AD.

    “Several GWAS studies have identified CLU as a significant genetic risk factor for sporadic AD (94, 119, 236, 343).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [119]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., Villa, S. E., Meechoovet, H. B., Gerber, J. D., Frost, D., Benson, H. L., O'Reilly, S., Chibnik, L. B., Shulman, J. M., Singleton, A. B., Craig, D. W., Van Keuren-Jensen, K. R., Dunckley, T., Bennett, D. A., De Jager, P. L., Heward, C., Hardy, J., Reiman, E. M., & Huentelman, M. J.
Affiliations
  • Translational Genomics Research Institute (US)
  • University of Miami (US)
  • Banner Alzheimer’s Institute (US)
  • Brigham and Women's Hospital (US)
  • National Institutes of Health (US)
  • Rush University Medical Center (US)
  • National Hospital for Neurology and Neurosurgery (GB)
Corresponding author
Huentelman, Matthew J.
Venue
Human Molecular Genetics
Published
2010-06-09
Volume
19
Issue
16
Pages
3295-3301
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2147719183
Cited by
237
References
38
Citations by year
2026: 3 · 2025: 4 · 2024: 11 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 13 · 2019: 12 · 2018: 23 · 2017: 15 · 2016: 16 · 2015: 17 · 2014: 18 · 2013: 21 · 2012: 34
FWCI
19.93
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • University of Miami
  • Rush University
  • Alzheimer's Society
  • Alzheimer's Research Trust
  • National Institute for Health and Care Research (P30AG10161)
  • Newcastle University (G0400074)
  • Stichting MS Research
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • North Bristol NHS Trust
  • Universitat de Barcelona
  • Hersenstichting
  • National Institutes of Health (1k01ag024079-01a2, AG19610)
  • Medical Research Council (G0400074)
  • NIHR Newcastle Biomedical Research Centre
  • National Institute on Aging (P30-AG 10161, P30-AG-19610, P50AG005144, AG-034504, P30AG028377, U01AG016976, K01-AG-024079, R01AG034504, AG-19610, P50AG016570, K08AG034290, P50AG005128, R01AG015819, P30AG010161, AG031581, R01AG031581, Z01AG000950, P50AG005681, P50AG008671, P30AG019610, P50AG005146, P50AG005136, P50AG005134)
  • National Institute of Mental Health (P50MH060451)
  • National Institute of Neurological Disorders and Stroke (R01NS059873, NS059873, P30 AG19610, P50NS039764)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, genetic association, complement receptor 1, clusterin, PICALM, apolipoprotein E, CST3, ACE, single nucleotide polymorphisms, genetic risk variants, imputation
MeSH terms
Alzheimer Disease, Apolipoproteins E, Gene Frequency, Genotype, Humans, Cohort Studies, Odds Ratio, Receptors, Complement 3b, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Monomeric Clathrin Assembly Proteins, Clusterin, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review